Sobering Results So Far for Biotech's Private Investors
This article was originally published in Start Up
Executive Summary
If venture capitalists were hoping to see a big profit, not merely liquidity, from a biotech IPO window, they've been seriously disappointed. Average step-up multiples for the seven biotech companies that went public in 2003 are quite low, especially compared to the heyday of 2000.